Four Deaths, One Drug, and the Future of Schizophrenia Treatment

To understand why this is such a gut punch, you need to know what evenamide was trying to do. Nearly every antipsychotic on the market works by blocking dopamine receptors in the brain. It's like having one tool in the toolbox: a hammer. Dopamine blockers help with hallucinations and delusions (the "positive symptoms" of schizophrenia), but they're terrible at treating the withdrawal, cognitive fog, and emotional flatness that make daily life so hard for patients.

Worse, about 30% of schizophrenia patients don't respond adequately to standard antipsychotics. For them, the options basically narrow down to clozapine, a drug so riddled with side effects that it requires regular blood monitoring.

Evenamide tried a completely different approach. Instead of blocking dopamine, it targets sodium channels in overactive brain cells to reduce excess glutamate release. Glutamate is the brain's main excitatory chemical messenger. In schizophrenia, certain brain circuits fire too much, flooding downstream pathways with glutamate and throwing dopamine signaling out of whack. Evenamide's pitch was simple: quiet the hyperactive circuits at the source, and the downstream chaos should settle down.

Newron called it a "first-in-class glutamate modulator," and the early data looked promising. A Phase 2/3 placebo-controlled trial of 291 patients showed evenamide beating placebo on the primary measure of symptom improvement (10.2 points vs. 7.6 on the PANSS scale, a standard schizophrenia rating tool). Tolerability looked clean, with roughly equal side-effect rates in both groups at about 25%.

The Phase 3 ENIGMA-TRS 2 trial was supposed to be the big confirmatory study: at least 400 patients, 12 weeks, focused squarely on treatment-resistant schizophrenia. That's the study now frozen in the U.S.

Not Dead Yet (but Definitely on Life Support)

Newron is trying to thread a needle here. The U.S. clinical hold stays in place, but enrollment continues at sites outside the United States. A separate study, ENIGMA-TRS 1, is expected to finish enrollment by mid-October 2026, with topline data due in the first quarter of 2027.

That upcoming readout becomes enormously important. If ENIGMA-TRS 1 shows strong efficacy with a clean safety profile, Newron has ammunition to negotiate with the FDA. If there are more safety flags, the whole program could be in jeopardy.

Historically, FDA clinical holds play out one of three ways. The company provides enough safety data to satisfy the agency and enrollment restarts. The program gets modified with tighter safety monitoring and continues under stricter conditions. Or the hold drags on so long that the program effectively dies.

A Crowded (but Incomplete) Playing Field

Evenamide's stumble comes at a complicated moment for the schizophrenia pipeline. The approval of KarXT in 2024 proved that non-dopamine mechanisms can work, opening the door for muscarinic receptor-targeting drugs. Several other novel approaches are moving through trials: NBI-1117568 (a muscarinic M4 agonist) and brilaroxazine (heading toward a regulatory filing).

But none of these are silver bullets for treatment-resistant patients. That population remains one of the biggest unmet needs in all of psychiatry, and evenamide was one of the few programs designed specifically for them.

Losing evenamide wouldn't just be bad for Newron. It would be a setback for the entire glutamate hypothesis of schizophrenia, a theory that has been kicking around neuroscience for decades but has never produced an approved drug. Every failed glutamate program makes the next one harder to fund.

What Comes Next

The key variables are straightforward. Can Newron convince the FDA that the deaths weren't caused by the drug's effect on heart rhythms? Will the ENIGMA-TRS 1 data, expected in early 2027, provide the safety reassurance regulators need? And is there a protocol modification (more cardiac monitoring, different patient selection) that could satisfy the agency without torpedoing the trial's feasibility?

For now, evenamide sits in regulatory limbo. Four deaths don't automatically condemn a drug; schizophrenia patients already face elevated mortality from cardiovascular disease, suicide, and other causes. But four deaths with no clear explanation and a plausible cardiac mechanism? That's exactly the kind of question the FDA was built to ask.

The answer will determine whether schizophrenia treatment gets its most genuinely novel option in years, or whether the glutamate hypothesis adds another entry to its long list of almost-but-not-quite stories.

Roche Is Hiring a Chinese Startup to Invent Its Next Cancer Drug

Roche signed a deal worth up to $1 billion with Defand Therapeutics, a two-year-old Chinese startup with zero clinical trials, to discover molecular glue cancer drugs. It's Roche's fourth China partnership since August, and it signals a radical shift in how big pharma thinks about drug discovery.